Methylene blue and cognition: what the human evidence really shows

Why researchers got interested

Methylene blue is a dye that can both accept and give up electrons. In cells, that lets it act as a stand-in electron carrier in the mitochondria, the structures that produce energy. Neurons are heavy energy users, so the idea that methylene blue might help struggling brain cells keep up is biologically plausible.

In lab and animal studies, low doses have supported mitochondrial function and been linked to better memory performance and some protective effects. Those findings are why the compound attracted attention, but animal results often fail to carry over to people.

The 2016 brain imaging study

The study most often quoted was published in Radiology in 2016 by researchers at the University of Texas. It was a randomized, double-blind, placebo-controlled trial in 26 healthy adults aged 22 to 62. Each person had functional MRI scans before and one hour after a single low oral dose of methylene blue or placebo while doing attention and short-term memory tasks.

Methylene blue increased activity in brain regions involved in attention and memory, and correct responses during memory retrieval rose by about 7 percent compared with baseline. The authors concluded low-dose methylene blue could enhance memory retrieval.

Reading that study carefully

• Small: 26 participants is enough to spot a signal, not to settle a question
• Single dose: it tells us nothing about weeks or months of use, or whether effects fade
• Short window: results were measured one hour after dosing
• Lab tasks: better scores on a test in a scanner are not the same as clearer thinking at work
• Not repeated at scale: larger confirmatory studies in healthy adults have not been published

Mood studies are a different question

Methylene blue has also been tested as an add-on treatment in bipolar disorder, where higher doses were linked to some improvement in depression and anxiety scores in a small crossover trial. Those studies measured mood in a specific psychiatric population, not memory or focus in healthy people, and they do not show it works as a general cognitive enhancer. Because methylene blue interacts dangerously with many psychiatric medicines, this is territory for specialist care only.

The Alzheimer's trials

The biggest test of the idea came from a modified form of methylene blue called LMTM, developed to block tau protein clumping in Alzheimer's disease. In a phase 3 trial published in The Lancet in 2016, 891 people with mild to moderate Alzheimer's were randomized. Neither dose showed benefit over the control on the co-primary measures of thinking and daily function at 65 weeks.

The developer has argued for benefit in some subgroups and later analyses, but these claims are debated and LMTM is not approved for Alzheimer's in the United States. LMTM is also a different formulation from the methylene blue sold as a supplement or compounded capsule.

So is methylene blue a nootropic?

Calling it one overstates what is known. There is a plausible mechanism, supportive animal work and one small single-dose human study with an encouraging signal. There is no long-term trial in healthy adults showing better memory, focus or protection against cognitive decline, and the largest trials in disease were negative.

That does not mean no one could ever benefit. It means any trial of methylene blue for brain fog should be framed as an experiment, with clear goals, careful safety screening and a willingness to stop.

How to judge a trial on yourself

If you and your clinician decide to try methylene blue, set it up so you can actually tell whether it helps. Write down two or three specific problems before starting, such as losing your train of thought in afternoon meetings or needing to reread emails. Rate them weekly for a few weeks before and after starting. Keep sleep, caffeine and alcohol as steady as you can, since they shift focus more than most supplements. If nothing has clearly changed after the agreed period, that is a useful answer too.

Before trying it for brain fog

Brain fog in midlife often has identifiable causes: poor sleep or sleep apnea, perimenopause, low thyroid, low B12 or iron, depression, alcohol, and medicines with sedating effects. These are worth checking first, because treating them can make a larger difference than any supplement.

Safety and how HealifyMD prescribes

Methylene blue is an MAO-A inhibitor and can cause serotonin syndrome with SSRIs, SNRIs and other serotonergic drugs, and it is contraindicated in G6PD deficiency. HealifyMD clinicians screen for both before prescribing. Our methylene blue is a compounded oral preparation from a licensed U.S. pharmacy; compounded medicines are not FDA-approved, and using it for cognition is off-label. The price is from $149/month, or $299 for 3 months ($100/month), confirmed at your eligibility review.